Boston Scientific (NYSE:BSX) today announced it completed the acquisition of Apollo Endosurgery.
The acquisition was announced in November and had an enterprise value of approximately $615 million.
Apollo Endosurgery’s product portfolio includes devices used during endoluminal surgery (ELS) procedures. The ELS procedures close gastrointestinal defects, manage gastrointestinal complications and aid in weight loss. ELS procedures are a less-invasive alternative to open and laparoscopic surgery. It also provides a quicker recovery to minimize the risks of surgical complications.